Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Prelude Therapeutics Inc (PRLD)
|
Add to portfolio |
|
|
|
| Price: |
$11.43
| | Metrics |
| OS: |
54.8
|
M
| |
|
|
| Market cap: |
$626
|
M
| |
|
|
|
Net cash:
|
$484
|
M
| |
$8.82
|
per share
|
|
EV:
|
$143
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 92.9 | 0.0 | 86.8 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | 7.0% | | | | | |
| Cost of goods sold | 0.0 | 123.5 | 0.0 | 113.7 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | -30.7 | 0.0 | -27.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | -33.0% | | -31.1% | | | |
| Selling, general and administrative | 123.5 | | 113.7 | | | | |
| Research and development | | | | | 48.2 | 24.3 | 12.6 |
| General and administrative | | 30.7 | | 27.0 | 10.6 | 3.8 | 2.4 |
| EBIT | 0.0 | -123.5 | 0.0 | -113.7 | -58.8 | -28.1 | -15.0 |
| EBIT margin | | -133.0% | | -131.1% | | | |
| Pre-tax income | -115.4 | -115.4 | -111.7 | -111.7 | -56.9 | -27.6 | -14.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -115.4 | -115.4 | -111.7 | -111.7 | -56.9 | -27.6 | -14.7 |
| Net margin | | -124.3% | | -128.7% | | | |
| |
| Diluted EPS | ($2.44) | ($2.44) | ($2.43) | ($2.43) | ($4.56) | ($16.52) | ($10.46) |
| Shares outstanding (diluted) | 47.4 | 47.4 | 46.0 | 46.0 | 12.5 | 1.7 | 1.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|